<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02603575</url>
  </required_header>
  <id_info>
    <org_study_id>BeijingCYHRICU01</org_study_id>
    <nct_id>NCT02603575</nct_id>
  </id_info>
  <brief_title>Effects and Safety of Caspofungin and Corticosteroids in Pneumocystis Pneumonia in Non-HIV Patients</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Beijing Chao Yang Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Beijing Chao Yang Hospital</source>
  <brief_summary>
    <textblock>
      Pneumocystis Pneumonia is increasing in Immunocompromised Non-HIV Infected Patients. The
      effects and safety of caspofungin and corticosteroids is not certain in this population. All
      Immunocompromised Non-HIV patients with respiratory failure were randomized into caspofungin
      and non-caspofungin group and corticosteroids and non-steroids group. The major outcome is 28
      day mortality, the second outcome are time of respiratory rate decreases to less than 25
      breath per minute, body temperature lower than 37.3℃.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>November 2015</start_date>
  <primary_completion_date type="Anticipated">December 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>mortality</measure>
    <time_frame>28 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time for release of fever</measure>
    <time_frame>2 days</time_frame>
    <description>Time for body temperature less than 37.3℃ for 48 hours</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time for release of respiratory distress</measure>
    <time_frame>2 days</time_frame>
    <description>Time for respiratory rate &lt;25 breathes per minute for 48 hours</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Pneumocystis Pneumonia</condition>
  <arm_group>
    <arm_group_label>Caspofungin and corticosteroids</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>patients treat with caspofungin and corticosteroids on the base of sulfanilamide</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Caspofungin and no corticosteroids</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>patients treat with caspofungin on the base of sulfanilamide</description>
  </arm_group>
  <arm_group>
    <arm_group_label>corticosteroids and no caspofungin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>patients treat with corticosteroids on the base of sulfanilamide</description>
  </arm_group>
  <arm_group>
    <arm_group_label>no corticosteroids and no caspofungin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>patients treat with sulfanilamide only</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>caspofungin</intervention_name>
    <description>70mg ivdrip the first day, then 50mg ivdrip qd</description>
    <arm_group_label>Caspofungin and corticosteroids</arm_group_label>
    <arm_group_label>Caspofungin and no corticosteroids</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>corticosteroids</intervention_name>
    <description>40mg ivdrip q12h for 5 days 40mg ivdrip qd for 5 days 20mg po for 11 days</description>
    <arm_group_label>Caspofungin and corticosteroids</arm_group_label>
    <arm_group_label>corticosteroids and no caspofungin</arm_group_label>
    <other_name>methylprednisolone</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sulfanilamides</intervention_name>
    <description>1.92g q8h</description>
    <arm_group_label>Caspofungin and corticosteroids</arm_group_label>
    <arm_group_label>Caspofungin and no corticosteroids</arm_group_label>
    <arm_group_label>corticosteroids and no caspofungin</arm_group_label>
    <arm_group_label>no corticosteroids and no caspofungin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Immunocompromised Non-HIV Infected Patients

          -  Partial arterial O2 pressure(PaO2)/FiO2≤300mmHg

          -  Diagnosed as Pneumocystis Pneumonia

        Exclusion Criteria:

          -  younger than 16 years old

          -  severe organ failure

          -  allergic to sulfanilamide, caspofungin or corticosteroid
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>16 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Hangyong He, MM</last_name>
    <phone>861013693585722</phone>
    <email>yonghang2004@sina.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Beijing Chao Yang Hospital</name>
      <address>
        <city>Beijing</city>
        <zip>100020</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hangyong He, MM</last_name>
      <phone>861085231543</phone>
      <email>cyh_birm@sina.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>November 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 8, 2015</study_first_submitted>
  <study_first_submitted_qc>November 10, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 13, 2015</study_first_posted>
  <last_update_submitted>November 10, 2015</last_update_submitted>
  <last_update_submitted_qc>November 10, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 13, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Beijing Chao Yang Hospital</investigator_affiliation>
    <investigator_full_name>Hangyong He</investigator_full_name>
    <investigator_title>Doctor</investigator_title>
  </responsible_party>
  <keyword>Caspofungin</keyword>
  <keyword>corticosteroids</keyword>
  <keyword>Pneumocystis Pneumonia</keyword>
  <keyword>Immunocompromised</keyword>
  <keyword>Non-HIV</keyword>
  <keyword>respiratory failure</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pneumonia</mesh_term>
    <mesh_term>Pneumonia, Pneumocystis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Methylprednisolone</mesh_term>
    <mesh_term>Caspofungin</mesh_term>
    <mesh_term>Echinocandins</mesh_term>
    <mesh_term>Sulfanilamide</mesh_term>
    <mesh_term>Sulfanilamides</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

